CYP2D6 enzyme

Amitriptyline and the enzyme CYP2D6

Amitriptyline is processed to a large extent by the enzyme CYP2D6.

Initially, amitriptyline is metabolised (demethylated) by the enzyme CYP2C19 into another active substance (nortriptyline). The enzymes CYP2C9 and CYP3A4 are also involved in this step to a lesser extent. After this activation step this substance is metabolised further (hydroxylated) by the enzyme CYP2D6 into less active components.

The activity of the enzymes concerned can vary considerably depending on your genetic predisposition, which means the efficacy of amitriptyline can also differ from person to person. Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with amitriptyline.

Atomoxetine and the enzyme CYP2D6

Atomoxetine is processed to a large extent by the enzyme CYP2D6. The activity of this enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of atomoxetine can also differ from person to person.

Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with atomoxetine.

Clomipramine and the enzymes CYP2D6 and CYP2C19

Clomipramine is processed to a large extent by the enzymes CYP2D6 and CYP2C19.

Initially, clomipramine is metabolised (demethylated) by the enzyme CYP2C19 into another active substance. The enzymes CYP1A2 and CYP3A4 are also involved in this step to a lesser extent. After this activation step this substance is metabolised further (hydroxylated) by the enzyme CYP2D6 into less active components.

The activity of the enzymes concerned can vary considerably depending on your genetic predisposition, which means the efficacy of clomipramine can also differ from person to person. Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with clomipramine.

Doxepin and the enzyme CYP2D6

Doxepin is processed to a large extent by the enzyme CYP2D6.

Initially, doxepin is metabolised (demethylated) by the enzyme CYP2C19 into another active substance. The enzymes CYP1A2, CYP2C9 and CYP3A4 are also involved in this step to a lesser extent. After this activation step this substance is metabolised further (hydroxylated) by the enzyme CYP2D6 into less active components.

The activity of the enzymes concerned can vary considerably depending on your genetic predisposition, which means the efficacy of doxepin can also differ from person to person. Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with doxepin.

Flecainide and the enzyme CYP2D6

Flecainide is processed to a large extent by the enzyme CYP2D6. The activity of this enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of flecainide can also differ from person to person.

Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with flecainide.

Imipramine and the enzymes CYP2D6 and CYP2C19

Imipramine is processed to a large extent by the enzymes CYP2D6 and CYP2C19.

Initially, imipramine is metabolised (demethylated) by the enzyme CYP2C19 into another active substance. The enzymes CYP1A2 and CYP3A4 are also involved in this step to a lesser extent. After this activation step this substance is metabolised further (hydroxylated) by the enzyme CYP2D6 into less active components.

The activity of the enzymes concerned can vary considerably depending on your genetic predisposition, which means the efficacy of imipramine can also differ from person to person. Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with imipramine.

Nortriptyline and the enzyme CYP2D6

Nortriptyline is processed to a large extent by the enzyme CYP2D6. The activity of this enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of nortriptyline can also differ from person to person. Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with nortriptyline.

*The enzyme CYP2C19 also plays a (limited) role in the processing of nortriptyline. However, no specific guidelines have been formulated on the basis of this enzyme.

Pimozide and the enzyme CYP2D6

Pimozide is processed to a large extent by the enzyme CYP2D6. The activity of this enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of pimozide can also differ from person to person.

Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with pimozide.

Risperidone and the enzyme CYP2D6

Risperidone is processed to a large extent by the enzyme CYP2D6. The activity of this enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of risperidone and the risk of side effects can also differ from person to person.

Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with risperidone.

Tramadol and the enzyme CYP2D6

Tramadol is processed to a large extent by the enzyme CYP2D6. The activity of this enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of tramadol can also differ from person to person.

Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with tramadol.

Zuclopenthixol and the enzyme CYP2D6

Zuclopenthixol is processed to a large extent by the enzyme CYP2D6. The activity of this enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of zuclopenthixol can also differ from person to person.

Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with zuclopenthixol.